BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients
- Maffioletti, Elisabetta
- Gennarelli, Massimo
- Gainelli, Giulio
- Bocchio-Chiavetto, Luisella
- Bortolomasi, Marco
- Minelli, Alessandra
Publication date
January 2020
DOI Publisher
Ovid Technologies (Wolters Kluwer Health)Abstract
Electroconvulsive therapy (ECT) represents one of the most effective therapies for treatment-resistant depression (TRD). The brain-derived neurotrophic factor (BDNF) is a neurotrophin implicated in major depressive disorder and in the effects of different therapeutic approaches, including ECT. Both BDNF peripheral levels and Val66Met polymorphism have been suggested as biomarkers of treatment effectiveness. The objective of this study was to test the potential of serum BDNF levels and Val66Met polymorphism in predicting ECT outcome in TRD patients
Add to ORKG